View in EDS

A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Saved in:
Bibliographic Details
Title: A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.
Authors: Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS., DiPersio JF; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Azzi J; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Cooper BW; Adult Hematologic Malignancies and Stem Cell Transplant, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH., Koehne G; Miami Cancer Institute, Baptist Health South Florida, Miami, FL., Koura D; University of California San Diego Moores Cancer Center, San Diego, CA., Maakaron J; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Magenau J; Department of Internal Medicine, University of Michigan, Ann Arbor, MI., McClune B; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT., Rimando JC; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Shah NN; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Suh HC; Division of Hematology Oncology, Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ., Beuka K; Vor Biopharma, Cambridge, MA., Sturrock J; Vor Biopharma, Cambridge, MA., Nikam M; Vor Biopharma, Cambridge, MA., Berglund E; Vor Biopharma, Cambridge, MA., Hu J; Vor Biopharma, Cambridge, MA., Keschner Y; Vor Biopharma, Cambridge, MA., Etchin J; Vor Biopharma, Cambridge, MA., Lydeard JR; Vor Biopharma, Cambridge, MA., Vasquez M; Vor Biopharma, Cambridge, MA., O'Donnell D; Vor Biopharma, Cambridge, MA., Mundelboim G; Vor Biopharma, Cambridge, MA., Thosar S; Vor Biopharma, Cambridge, MA., Canesin G; Vor Biopharma, Cambridge, MA., Xavier-Ferrucio J; Vor Biopharma, Cambridge, MA., Hyzy SL; Vor Biopharma, Cambridge, MA., Lloyd DM; Vor Biopharma, Cambridge, MA., Spink K; Vor Biopharma, Cambridge, MA., Hummel D; Vor Biopharma, Cambridge, MA., Lee-Sundlov MM; Vor Biopharma, Cambridge, MA., Scherer J; Vor Biopharma, Cambridge, MA., Lin MI; Vor Biopharma, Cambridge, MA., Whangbo JS; Vor Biopharma, Cambridge, MA., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Palo Alto, CA.
Source: Blood [Blood] 2026 Apr 23; Vol. 147 (17), pp. 1914-1927.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41636724
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Mushtaq+MU%22">Mushtaq MU</searchLink>; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22DiPersio+JF%22">DiPersio JF</searchLink>; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.<br /><searchLink fieldCode="AU" term="%22Azzi+J%22">Azzi J</searchLink>; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY.<br /><searchLink fieldCode="AU" term="%22Cooper+BW%22">Cooper BW</searchLink>; Adult Hematologic Malignancies and Stem Cell Transplant, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH.<br /><searchLink fieldCode="AU" term="%22Koehne+G%22">Koehne G</searchLink>; Miami Cancer Institute, Baptist Health South Florida, Miami, FL.<br /><searchLink fieldCode="AU" term="%22Koura+D%22">Koura D</searchLink>; University of California San Diego Moores Cancer Center, San Diego, CA.<br /><searchLink fieldCode="AU" term="%22Maakaron+J%22">Maakaron J</searchLink>; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN.<br /><searchLink fieldCode="AU" term="%22Magenau+J%22">Magenau J</searchLink>; Department of Internal Medicine, University of Michigan, Ann Arbor, MI.<br /><searchLink fieldCode="AU" term="%22McClune+B%22">McClune B</searchLink>; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT.<br /><searchLink fieldCode="AU" term="%22Rimando+JC%22">Rimando JC</searchLink>; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA.<br /><searchLink fieldCode="AU" term="%22Shah+NN%22">Shah NN</searchLink>; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Suh+HC%22">Suh HC</searchLink>; Division of Hematology Oncology, Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.<br /><searchLink fieldCode="AU" term="%22Beuka+K%22">Beuka K</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Sturrock+J%22">Sturrock J</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Nikam+M%22">Nikam M</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Berglund+E%22">Berglund E</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Hu+J%22">Hu J</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Keschner+Y%22">Keschner Y</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Etchin+J%22">Etchin J</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Lydeard+JR%22">Lydeard JR</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Vasquez+M%22">Vasquez M</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22O'Donnell+D%22">O'Donnell D</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Mundelboim+G%22">Mundelboim G</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Thosar+S%22">Thosar S</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Canesin+G%22">Canesin G</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Xavier-Ferrucio+J%22">Xavier-Ferrucio J</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Hyzy+SL%22">Hyzy SL</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Lloyd+DM%22">Lloyd DM</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Spink+K%22">Spink K</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Hummel+D%22">Hummel D</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Lee-Sundlov+MM%22">Lee-Sundlov MM</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Scherer+J%22">Scherer J</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Lin+MI%22">Lin MI</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Whangbo+JS%22">Whangbo JS</searchLink>; Vor Biopharma, Cambridge, MA.<br /><searchLink fieldCode="AU" term="%22Muffly+LS%22">Muffly LS</searchLink>; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Palo Alto, CA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2026 Apr 23; Vol. 147 (17), pp. 1914-1927.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41636724
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/blood.2025031053
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1914
    Titles:
      – TitleFull: A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Mushtaq MU
      – PersonEntity:
          Name:
            NameFull: DiPersio JF
      – PersonEntity:
          Name:
            NameFull: Azzi J
      – PersonEntity:
          Name:
            NameFull: Cooper BW
      – PersonEntity:
          Name:
            NameFull: Koehne G
      – PersonEntity:
          Name:
            NameFull: Koura D
      – PersonEntity:
          Name:
            NameFull: Maakaron J
      – PersonEntity:
          Name:
            NameFull: Magenau J
      – PersonEntity:
          Name:
            NameFull: McClune B
      – PersonEntity:
          Name:
            NameFull: Rimando JC
      – PersonEntity:
          Name:
            NameFull: Shah NN
      – PersonEntity:
          Name:
            NameFull: Suh HC
      – PersonEntity:
          Name:
            NameFull: Beuka K
      – PersonEntity:
          Name:
            NameFull: Sturrock J
      – PersonEntity:
          Name:
            NameFull: Nikam M
      – PersonEntity:
          Name:
            NameFull: Berglund E
      – PersonEntity:
          Name:
            NameFull: Hu J
      – PersonEntity:
          Name:
            NameFull: Keschner Y
      – PersonEntity:
          Name:
            NameFull: Etchin J
      – PersonEntity:
          Name:
            NameFull: Lydeard JR
      – PersonEntity:
          Name:
            NameFull: Vasquez M
      – PersonEntity:
          Name:
            NameFull: O'Donnell D
      – PersonEntity:
          Name:
            NameFull: Mundelboim G
      – PersonEntity:
          Name:
            NameFull: Thosar S
      – PersonEntity:
          Name:
            NameFull: Canesin G
      – PersonEntity:
          Name:
            NameFull: Xavier-Ferrucio J
      – PersonEntity:
          Name:
            NameFull: Hyzy SL
      – PersonEntity:
          Name:
            NameFull: Lloyd DM
      – PersonEntity:
          Name:
            NameFull: Spink K
      – PersonEntity:
          Name:
            NameFull: Hummel D
      – PersonEntity:
          Name:
            NameFull: Lee-Sundlov MM
      – PersonEntity:
          Name:
            NameFull: Scherer J
      – PersonEntity:
          Name:
            NameFull: Lin MI
      – PersonEntity:
          Name:
            NameFull: Whangbo JS
      – PersonEntity:
          Name:
            NameFull: Muffly LS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 04
              Text: 2026 Apr 23
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1528-0020
          Numbering:
            – Type: volume
              Value: 147
            – Type: issue
              Value: 17
          Titles:
            – TitleFull: Blood
              Type: main
ResultId 1